We investigated the ability ofpurified, recombinant DNA-derived interferons (IFN) to induce phenotypic changes in cells of the HL-60 promyelocytic leukemia cell line. Changes in cell surface markers detected by monoclonal antibodies as well as morphologic, histochemical, and functional changes were monitored. We found that gamma (y)IFN, but not alpha (a) or beta (3)IFN, induced the expression of antigens characteristic of monocytes and granulocytes (AML-2-23, 63D3, and 61 D3), as well as changes in morphology consistent with monocytoid differentiation. These included induction of a-naphthyl acetate esterase, increased cell size, and a decrease in azurophilic granules. The y-IFN dose dependency and time course ofthe effect on antigen expression suggest that de novo protein synthesis was induced by y-IFN. The activity of -y-IFN and of mixed-lymphocyte culture supernatant was blocked by a monoclonal antibody to y-IFN. Significant augmentation in the ability ofthe HL-60 cells to mediate antibody-dependent cellular cytotoxicity was induced by y-IFN. These findings suggest that y-IFN plays a role in the regulation of hematopoiesis.
Introduction
A number of studies have documented the ability of the HL-60 promyelocytic leukemia cell line to differentiate along either a granulocytic or monocytic pathway, depending upon the inducing agent used (1) (2) (3) (4) . Polar 
planar substances such as dimethyl
Receivedfor publication 22 September 1983 and in revisedform 8 December 1983. sulfoxide (DMSO)' or dimethylformamide and retinoic acid can induce striking granulocytic differentiation (1, 2) , while phorbol diesters and supernatants from stimulated lymphocytes have been shown to cause these cells to undergo monocytoid differentiation (3, 4) . Changes concomitant with morphologic differentiation also occur in the expression of cell surface antigens, some of which have been defined using monoclonal antibodies (MoAbs) (5) (6) (7) (8) (9) .
We have previously shown (9) that an antigen shared by monocytes and granulocytes, defined by MoAb AML-2-23, can be induced on cells of the HL-60 line by incubation with either granulopoietic inducers such as DMSO or by lymphocyte supernatants, but not by phorbol diester treatment. Induction of differentiation with mixed-lymphocyte culture supernatants (MLC-SUP) involved primarily the increased expression of cytoplasmic a-naphthyl acetate esterase (nonspecific esterase) and a decreased nuclear/cytoplasmic ratio. In contrast, treatment of the cells with phorbol diester induced more profound monocytoid differentiation resulting in many of the cells attaching to plastic surfaces and extending pseudopods. The factors present in MLC-SUP that induce neoantigen expression as well as histochemical and morphologic changes have previously been unknown. In this report, we present evidence that immune or gamma interferon (,y-IFN) is capable of mimicking the activity of MLC-SUP and we propose that this lymphokine is involved in the induction of differentiation in the HL-60 line.
Methods
Cells. The HL-60 promyelocytic leukemia cell line (10) was provided by Dr. Robert Gallo, of the National Institutes of Health, Bethesda, MD. Cells were continuously cultured in a serum-free defined medium (modified Iscove's medium [11] ). For comparison, a variety of other culture media were used, including RPMI-1640 (K. C. Biologicals, St. Louis, MO) supplemented with 10% fetal bovine serum (FBS) (Sterile Systems Inc., Logan, UT), Immunex modified Iscove's medium (Immunex, Inc., Seattle, WA), and Iscove's medium, supplied by K. C.
Biologicals. All media were supplemented with 50 14g/ml of gentamicin (Schering Corp., Kenilworth, NJ).
Monoclonal antibodies. MoAb AML-2-23, an IgG2b antibody that reacts strongly with monocytes and less so with granulocytes (8) was used in this study to monitor phenotypic changes. In addition, the reactivity of MoAbs PM-81(12), PMN 29(8) , PMN 6(8) , OKIal (Ortho Diagnostic Systems, Inc., Westwood, MA), 61D3 (13) , and 63D3 (13) with control and treated cells was determined. Control MoAbs included AML-1-201 (8) , which reacts with ,-2 microglobulin, the IgGI antibody produced by the P3 hybridoma parent cell line, and an IgG2b MoAb of irrelevant specificity. All studies were conducted with saturating amounts of purified MoAbs (20 sg/ml).
To quantify the number ofAML-2-23 binding sites, the Fab portion of MoAb AML-2-23 was prepared by papain cleavage (14) , affinity chromatography on protein A-Sepharose 4B, and gel filtration on Sephadex GI00, and was iodinated by the chloramine T method (15) . Control and treated cells were incubated for 2 h at 4VC with a saturating dose of '25l-Fab in the presence or absence of excess unlabeled MoAb AML-2-23. Free and bound antibody were separated by centrifugation on an oil cushion (16) and the radioactivity in supernatants and cell pellets was determined. After correcting for nonspecific binding, the number of AML-2-23 receptor sites per cell was estimated from the specific activity of the radiolabeled Fab.
Induction ofphenotypic change with IFN. a-, ,-, and 'y-IFN produced in Escherichia coli from recombinant human DNA (17) (18) (19) were generously provided by Dr. Costa Sevastopoulos (Genentech Inc., San Francisco, CA) for these studies. The purity of these preparations was >95% as established by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and silver staining (20) . The levels of endotoxin in IFN preparations and media were measured in a Limulus amebocyte assay (21) . Cells from the HL-60 line were seeded at 125,000 cells/ml in six-well plastic tissue culture plates to which were added varying concentrations of each of the IFN species. To establish a dose-response relationship, cells were cultured with increasing concentrations of interferons (0.1-104 anti-viral U/ml, a-IFN as standard) for 3 d at 37°C in a 5% CO2 humidified atmosphere and removed for morphologic evaluation and for binding to MoAbs. The morphology of treated and control cells was evaluated by Wright's-Giemsa stain on cytofuge preparations. Staining for a-naphthyl acetate esterase was also performed (22). MoAb binding was evaluated by cytofluorography. A study of the time dependency for 'y-IFN induction was performed during which 500 U of y-IFN was added serially on each of 7 d to cells previously seeded as above.
Blocking of y-IFN activity by a MoAb to y-IFN. To verify that the activity being measured in both the y-IFN preparations and MLC supernatants was y-IFN, we attempted to block activity with a MoAb to y-IFN. An IgGl MoAb that neutralizes 'y-IFN activity was generously provided for these studies by Drs. Junming Le and Jan T. Vilcek of New York University Medical Center. 100 U of -y-IFN (in 20 id) or MLC-SUP (20 u1) was incubated with 20 ul of supernatant (either diluted 1:10 with medium or undiluted) from the anti-y-IFN hybridoma, B-3, or the P3 myeloma cell line at 37°C for I h. This mixture was added to freshly seeded HL-60 cells. To control for the possibility that immune complexes could nonspecifically block y-IFN activity, we added a mixture of human nerve growth factor and an IgG MoAb specific for nerve growth factor to some cultures. In addition, to further ensure specificity, the B-3 MoAb was added to cultures in the presence of 1% DMSO. 5 d later, AML-2-23 antigen induction on these and control cells was determined by cytofluorography. In addition, the ability of these cells to mediate antibody-dependent cellular cytotoxicity (ADCC) was measured (see below).
Effect of colony-stimulating factor (CSF-1J) and endotoxin on HL-60 cells. HL-60 cells were cultured in serum-free medium with increasing concentrations of purified CSF-1 ( ADCC. ADCC was performed as previously described (23) . Briefly, chicken erythrocytes (CE) freshly drawn into heparin were washed once and 10 1d of pelleted cells were labeled with 100 gCi [5" Cr]sodium chromate (New England Nuclear, Boston, MA). Effector HL-60 cells, cultured as indicated, were mixed in round-bottomed microtiter wells with an equal volume of labeled CE (1 X 105/ml) and a 10-1 dilution of a rabbit anti-CE IgG fraction (stock solution 16 mg/ml). After 6 h incubation at 37°C, half the supernate was removed and assessed for 5'Cr content. Results are expressed as mean±SD of triplicate wells. 
Results
Induction of morphologic change. Approximately 50% of cells cultured in the presence of y-IFN exhibited a lower nuclear/ cytoplasmic ratio and the loss of azurophilic granules. The cells remained in suspension and did not attach to the plastic culture wells. Sorting of these cells by fluorescence on the cytofluorograph and observation of their morphology on cytofuge preparations revealed that AML-2-23-positive cells were a homogeneous population of large cells with abundant agranular cytoplasm. Staining oftreated cells for nonspecific esterase revealed that -60% of cells were induced by Sy-IFN to display strong cytoplasmic staining while control cells were all negative. aand f,-IFN did not induce such morphologic or histochemical changes. Proliferation of HL-60 cells was decreased by only 20% during exposure to a-and fl-IFN for 6 d while y-IFN had no effect, as determined by [3H]thymidine incorporation. Cells treated with IFN and control cells were >95% viable as determined by staining with acridine orange and ethidium bromide.
Measurement ofmonoclonal antibody binding to cells. The percentage of untreated HL-60 cells bearing the AML-2-23 antigen varied with the medium used. Less than 10% of the cells cultured in serum-free modified Iscove's medium expressed the AML-2-23 antigen even when endotoxin at concentrations ranging from 0.01 to 103 ng/ml or CSF-1 (1-500 U/ml) was added (data not shown). The activity of CSF-1 was verified by its ability to support growth of colonies derived from peripheral blood mononuclear cells of normal donors in methylcellulose cultures (24). Cells cultured in RPMI containing 10% FBS, or in Immunex medium, expressed the AML-2-23 antigen on -15-40% of cells probably in response to differentiating agents such as retinoids which are found in serum.
The experiment shown in Fig. 1 indicates that -50% of HL-60 cells were induced by y-IFN to express the AML-2-23 antigen. In six experiments, the range of AML-2-23 positive cells following y-IFN treatment was 50-75%. The effect of y-IFN was near maximal by day 5 in experiments in which cells were cultured in medium to which 500 U/ml y-IFN was initially added (Fig. 2) . To control for the possibility that the AML-2-23 antibody may interact with induced HL-60 cells through Fcreceptors (25) , competing human IgG at 300 ,g/ml was mixed with AML-2-23 before incubation with treated cells. The degree ofbinding ofAML-2-23 was unaffected by Fc-receptor blockade. Radioligand binding data (not shown) using '25I-Fab ofthe AML-2-23 MoAb indicated that the average number of antigenic determinants increased from -6,000/cell to 90,000/cell during culture in the presence of 500 U/ml y-IFN. Cells cultured in the presence of a-and fi-IFN revealed no change in the level of AML-2-23 antigen (<10% positive). The degree of induction of the AML-2-23 antigen by MLC-SUP was similar to that of 'y-IFN at 500 U/ml. No in parallel with AML-2-23, as previously reported (9) . OKIal did not bind to HL-60 cells before or after IFN exposure. Of interest is that the expression of f,-2-microglobulin was found to be quite low on control cells cultured in serum-free medium and that y-IFN was capable of inducing this antigen.
Effect ofanti-'y-IFNMoAb on activity ofry-IFNand ofMLC-SUP. As seen in Table II, (Table II) ADCC. Unstimulated HL-60 cells possessed low levels of cytotoxicity to antibody-coated CE, with -10% specific cytotoxicity at a ratio of 10 HL-60 cells to 1 CE (Fig. 3 ). Cells cultured for 5 d under identical conditions in the presence of y-IFN showed a three to fourfold increase in killing. This demonstrates that recombinant human y-IFN is a potent inducer of ADCC by HL-60 cells, in line with a previous report that IgG Fc receptor expression by this cell line is greatly elevated by recombinant y-IFN (26) . Cells cultured with 10 U/ml y-IFN in the presence of the MoAb specific for y-IFN, B-3, did not show such strongly elevated cytotoxicity (Fig. 3 ). Although these cells still killed more effectively than untreated controls, the level of cytotoxicity was only half of that achieved by cells treated with 10 U/ml y-IFN.
Since the degree of cytotoxicity of y-IFN treated cells was nearly identical over a range of effector to target ratios from 10 to 1.2, other experiments were performed in which lower effector to target ratios were achieved. As shown in Fig. 4 the degree of killing was dependent on the ratio of effector to target cells at low effector to target ratios. Also of interest is the observation that treatment of HL-60 cells with DMSO did not induce in- incubated with an equal volume of supernatant from the hybridoma producing anti-IFN MoAb, B-3, or control supernatant (CON) (from the P3 myeloma line) for I h at 370C. This mixture was added in duplicate to HL-60 cells freshly seeded (3 X 105 cells/ml) into 24-well cluster plates. In experiment 2, a mixture of an irrelevant immune complex (IC) (nerve growth factor-anti-nerve growth factor) was added to some cultures to control for the possibility that immune complexes accounted for the inhibition of y-IFN by B-3. CON in this experiment was supernatant from 7SN-60-4, a murine hybridoma producing an anti-nerve growth factor IgG MoAb. In both experiments, parallel cultures of HL-60 cells in the presence of y-IFN (100 U/ml) or MLC-SUP (2% in experiment 1, 10% in experiment 2) were also conducted. After culture for 5 d, these cells were analyzed by cytofluorography for the expression of the AML-2-23 antigen. The creased ADCC activity despite the fact that granulocytic differentiation and neoantigen expression (AML-2-23) was induced on these cells.
Another experiment ( Fig. 5 ) demonstrates blocking of MLC-SUP-mediated induction of ADCC by the B-3 MoAb, further supporting the notion that y-IFN is the active factor in MLC-SUP.
Discussion
These studies indicate that y-IFN induces phenotypic changes consistent with monocytoid differentiation in cells of the HL-60 promyelocytic leukemia cell line. We have previously shown that MLC-SUP are capable of inducing an identical change in the phenotype of HL-60 cells and the present report now demonstrates that this effect is duplicated by gene-cloned and essentially pure y-IFN. Neither purified CSF-1 nor endotoxin were capable of inducing these effects. Since the 'y-IFN concentration dependence of this effect is consistent with the levels of y-IFN normally present in MLC-SUP, it would appear that the component in MLC-SUP primarily responsible for induction of monocytoid differentiation is -y-IFN. This interpretation is supported by the finding that the activity of both the cloned y-IFN and MLC-SUP was blocked by a specific MoAb to y-IFN. However, some contribution of other factors cannot be definitively excluded. Moreover, we have shown that the changes induced by y-IFN are specific to this species of IFN and not induced by either a-or f3-IFN. The lack of effects with a-and (-IFNs are consistent with a recent report (27) also showing that no morphologic, antigenic, or functional changes were induced in the U937 line by these species of IFN. In addition, these results demonstrate that the antigenic and morphologic changes induced by y-IFN are accompanied by an increase in ADCC mediated by these cells. Since the ability to kill antibody-coated targets is a recognized property of mature cells of the myeloid series, this increase in cytotoxic capability appears to be related to overall differentiation of HL-60 cells.
Other data, however, suggest that this interpretation may be an over-simplification. In particular, cloned 'y-IFN has been shown to elevate Fc receptors (26) on HL-60 and U937 cells (26) and ADCC of U937 cells within 18 h (28) although differentiation of HL-60 as assessed by appearance of the AML-2-23 antigen did not occur until 48 h. It is possible, therefore, that y-IFN enhancement of myeloid Fc receptor expression and ADCC may not be directly linked to differentiation. Further evidence in support of this notion is the failure of DMSO to induce ADCC despite the fact that this agent induces granulocytic differentiation of HL-60 cells (9) .
The results of our study and of others (29, 30) indicate that IFN has important effects on hematopoiesis. Our findings also suggest the possibility that human y-IFN may play a regulatory role in the process of monocyte/macrophage commitment from the myeloid progenitor pool as well as functional activation of these cells. It is interesting that not all HL-60 cells were inducible by y-IFN, in contrast to the effects of chemical inducers such as DMSO or phorbol diester. We are presently studying the inducibility of individual clones of HL-60, in order to identify noninducible clones, and, therefore, identify differences between noninducible and inducible cells.
That y-IFN induces monocytoid changes in the phenotype of HL-60 cells may have clinical significance. If cells from patients with acute myelogenous leukemia respond to y-IFN in a similar manner, this agent could have therapeutic use as a differentiation agent, possibly in combination with other known differentiating agents such as the retinoids or 1,25-dihydro;iyvitamin D3. In addition to the possibility of terminally differentiating the leukemic clone, the induction of neoantigen expression could enhance MoAb-mediated cytolysis. Further studies that address these possibilities with both the HL-60 cell line and leukemia cells from patients with AML are in progress.
